Skip to main content
Premium Trial:

Request an Annual Quote

DeRisi Lab Helps CDC Identify SARS Virus By Using its Long-Oligo Virus Microarray


Joseph DeRisi's laboratory at the University of California at San Francisco used microarray analysis to help identify as a coronavirus the disease that has killed almost 20 people and has spread from China and Vietnam throughout the globe, according to an article published in the San Francisco Chronicle Tuesday.

The illness, called SARS (severe acute respiratory syndrome) has mystified health authorities.

The US Centers for Disease Control and Prevention in Atlanta said the previously unknown coro-navirus was identified over the weekend during testing conducted on samples from Vietnam, Hong Kong, and Singapore.

DeRisi, assistant professor of biochemistry and biophysics, used a microarray containing, “every known, completely sequenced virus,” the article said.

In research published in the journal Proceedings of the National Academy of Science, Nov. 26, 2002, DeRisi's lab described “Microarray-based detection and genotyping of viral pathogens.” The paper described a long-oligonucleotide (70-mer) microarray capable of detecting hundreds of viruses. Elements from conserved regions within viral families facilitate identification of viruses whose sequences are not on the array.


The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.